In content advertising company Mirriad Advertising (LON: MIRI) has clawed back some of last week’s share price fall after it said it was running out of money and the business may have to be placed into administration. There has been no positive update since then, but the share price rebounded 8.33% to 0.0325p.
Kefi Gold and Copper (LON: KEFI) says that its partner in the Tulu Kapi gold project, Africa Finance Corporation, has been approved for Ethiopian Country Membership. This will help with project financing. The share price improved 5.47% to 0.675p.
Helium One Global (LON: HE1) has drilled the Jackson-2 well in Colorado has been drilled to 375 metres and free gas has been confirmed. Samples have been sent to the laboratory for analysis of helium and CO2 content. The share price rose 2.78% to 0.925p.
Aptamer (LON: APTA) says the Optimer-based test for Alzheimer’s disease has been adapted into an Enzyme-Linked Immunosorbent Assay (ELISA), a format widely accepted and used in hospital laboratories. This has enabled a royalty agreement to be finalised with development partner Neuro-Bio. Aptamer will receive a blended royalty rate of 11.1% on the first £166m of sales with 5% after that level of sales is passed. A validated prototype could be developed within 18 months and the be transferred to a distributor. The Alzheimer’s disease testing market could be worth $19.6bn by 2029. The share price is 1.3% ahead at 0.39p, having been 0.42p earlier in the day.
FALLERS
Trading recommenced in Argentix (LON: AGFX) shares following the financial problems due to taking on too much risk on foreign currency transactions and the recommended bid of 2.49p/share from IFX Payments. The share price slumped 91.9% to 3.485p, but remains above the bid price.
Film and TV vehicles and trailer supplier Facilities by ADF (LON: ADF) reported 2024 figures in line with expectations, but the figures were overshadowed by potential US tariffs on non-US movies. This provides additional uncertainty in a market that has been slow to recover from the US writers; strike and concerns that there could have been changes in UK film and TV investment incentives. There was a small 2024 pre-tax profit before exceptionals, including a £2.45m write down of goodwill on the acquisition of Location One, which has not performed to expectations. First quarter group revenues have improved, and pre-tax profit should recover this year. The share price dipped 16% to 14.5p.
Fusion Antibodies (LON: FAB) confirms 2024-25 revenues were £1.96m, up from £1.14m, with £400,000 of cash in the bank. The estimated loss is £1.5m. Gross margins remain well below the 50% achieved in the past. Concerns about US tariffs provides a headwind for the business, which should grow revenues again this year. The share price declined 5.34% to 6.2p.
Excess inventory retailer Huddled (LON: HUD) reported a jump in 2024 revenues from £2.4m to £14.2m through a combination of growth in the original Discount Dragon fast moving consumer products retailer and the acquisitions of cosmetic products retailer Boop Beauty and health products retailer Nutricircle. The legacy Let’s Connect business is being closed down. The 2024 loss increased from £2.28m to £4.05m. First quarter trading has been strong and there is additional warehouse capacity that will enable Huddled to move towards profitability later this year. A £1.1m loss is forecast for 2025 and a move into profit anticipated in 2026. The share price fell 5.88% to 3.2p.